Artesunate / Mefloquine Tablets are a fixed‑dose artemisinin‑based combination therapy (ACT) for the treatment of acute uncomplicated malaria.
Artesunate: Fast‑acting artemisinin derivative that rapidly reduces parasite load and relieves fever and clinical symptoms.
Mefloquine: Long‑acting blood schizonticide that eliminates remaining parasites and prevents recrudescence.
This combination provides potent synergistic activity, high cure rates, and helps delay the emergence of drug‑resistant malaria parasites.
Indications
For the treatment of acute uncomplicated malaria caused by Plasmodium falciparum (including multidrug‑resistant strains) and Plasmodium vivax in adults and children.
Key Features
Rapid parasite clearance and early symptom relief
High efficacy against drug‑resistant falciparum malaria
Convenient 3‑day oral treatment course
Good compliance and well‑established safety profile
Suitable for use in endemic areas and travelers
Manufactured under strict GMP conditions
Complies with WHO, USP, EP pharmacopoeial standards
Full registration dossiers available for global market registration
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Important Note
Prescription‑only medicine.
Contraindicated in patients with hypersensitivity to artesunate, mefloquine, or related compounds.
Use with caution in patients with epilepsy, psychiatric disorders, cardiac conduction abnormalities, or hepatic/renal impairment.
Not intended for severe malaria; parenteral treatment is required.
Should be administered under medical supervision.
